GlucoTrack, Inc. (GCTK) News
Follow GlucoTrack, Inc. (GCTK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 34 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nasdaq to Delist Glucotrack After Listing-Rule Exception Failure
Nasdaq notified Glucotrack on October 28 that its securities would be delisted after the closing bid price fell to $0.87 on October 14, failing the terms of an exception to Nasdaq Listing Rule 5550(a)(2). Trading is sche
REGULATION | Oct 29, 2026, 09:05 PM UTC
M
Nasdaq halts trading due to volatility
EQUITY | Oct 29, 2026, 05:17 PM UTC
M
Glucotrack Raises $2 Million in Convertible-Note Financing
Glucotrack raised $2 million in a private placement, issuing senior secured convertible notes with $2.56 million in principal and warrants to purchase 8.03 million shares. The notes carry 8% annual interest and mature in
EQUITY | Oct 22, 2026, 09:33 PM UTC
L
Glucotrack Tightens Anti-Dilution Terms Across Notes and Warrants, Sets Absolute Conversion Floor
Glucotrack executed a series of amendments to multiple securities beginning September 22, 2026, aimed at reducing dilution and improving pricing certainty. The company amended its Bridge Warrants and September Warrants t
NEWS | Sep 28, 2026, 09:36 PM UTC
L
Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the upcom
NEWS | Sep 25, 2026, 01:03 PM UTC
L
Glucotrack Prices $3.1 Million Registered Direct Offering of Stock and Pre-Funded Warrants
Glucotrack entered a series of agreements to complete a registered direct offering expected to raise approximately $3.1 million. The Securities Purchase Agreement covers 169,388 shares and pre-funded warrants to purchase
EQUITY | Sep 24, 2026, 09:24 PM UTC
L
Glucotrack, Inc. (GCTK) Prices $3.1M Offering
Glucotrack priced a best-efforts public offering for ~$3.1M gross, including 169,388 shares at $2.04 and pre-funded warrants for up to 1,350,220 shares at $2.039. Closing is expected on or about Sep 25, 2026, subject to
EQUITY | Sep 24, 2026, 12:45 PM UTC
L
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of co
EQUITY | Sep 24, 2026, 12:45 PM UTC
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblasto
NEWS | Sep 23, 2026, 08:30 PM UTC
L
Glucotrack issues strategic update: LT-100 clinical study targeted, ai² platform expands university network
Glucotrack provided a strategic update highlighting near-term LT-100 clinical plans and growth of its ai² discovery and talent platform.Key Highlights:Original SEC Filing: Glucotrack, Inc. [ GCTK ] - 8-K - Sep. 23, 2026T
REGULATION | Sep 23, 2026, 01:24 PM UTC
L
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeuti
NEWS | Sep 23, 2026, 01:01 PM UTC
L
Glucotrack Amends PIPE Warrants to Require Shareholder Approval Under Nasdaq Rule 5635(d)
Glucotrack entered into an amendment to its Common Warrants issued in the August 4, 2026 private placement. The change prevents any warrant exercises or related share issuances until stockholders approve the full issuanc
NEWS | Sep 14, 2026, 08:24 PM UTC
L
Glucotrack Closes $11.6M Senior Secured Convertible Notes; Generates $4.5M Cash in Private Placement
Glucotrack completed a private placement, issuing $11.6 million in senior secured convertible notes to raise $4.5 million in cash and refinance $4.55 million of existing notes. The notes carry 8% interest, mature in nine
NEWS | Sep 11, 2026, 09:24 PM UTC
M
Glucotrack announces $11.5 million convertible notes financing
Glucotrack said it has definitive agreements for convertible notes totaling about $11.5 million, including roughly $4.5 million of new cash investment and about $4.5 million from existing notes.
EQUITY | Sep 11, 2026, 12:00 PM UTC
L
GlucoTrack settlement: $2 million initial payment to Alto Opportunity Master Fund
GlucoTrack said it entered a settlement agreement related to debt owed to Alto Opportunity Master Fund by Apimeds Pharmaceuticals US. The company will make an initial payment of $2 million and pay another $2 million unde
EQUITY | Sep 09, 2026, 10:19 PM UTC
L
Glucotrack settles with Alto, paying $2.0M cash and issuing $2.0M 5% note
Glucotrack entered a settlement with Alto and related parties to resolve disputes tied to asserted $10.9 million indebtedness. The company will pay $2.0 million in cash and issue a $2.0 million 5% convertible note amorti
MNA | Sep 09, 2026, 09:05 PM UTC
L
GCTK subsidiary Lōkahi expands ai² platform into three divisions
Lōkahi Therapeutics Inc., a subsidiary of Glucotrack Inc. (NASDAQ: GCTK), said it is expanding its ai² platform into three business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™.
EQUITY | Sep 08, 2026, 01:15 PM UTC
L
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening
EQUITY | Sep 02, 2026, 01:15 PM UTC
L
Glucotrack announces 1-for-15 reverse split and CUSIP update
Glucotrack announced a 1-for-15 reverse split to reduce shares and a CUSIP update.
EQUITY | Aug 27, 2026, 12:54 PM UTC
M
GCTK Glucotrack Announces $5.5 Million Financing
GCTK Glucotrack raises $5.5 million
EQUITY | Aug 05, 2026, 12:34 PM UTC
L
GCTK - Lōkahi Therapeutics™ ai ² Futures Lab™ Changes How Biopharma Builds a Pipeline
GCTK - Lōkahi Therapeutics™ ai ² Futures Lab™ Changes How Biopharma Builds a Pipeline
EQUITY | Jul 31, 2026, 12:10 PM UTC
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
H
NUWE Soars 170%
Nuwellis stock jumps on study acceptance
EQUITY | Jul 30, 2026, 01:05 PM UTC
H
Premarket Gainers: NUWE +100%
NUWE leads premarket gainers
EQUITY | Jul 30, 2026, 09:32 AM UTC
H
Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Shares of Microsoft Corp (NASDAQ: MSFT ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Microsoft reported fourth-quarter revenue of $90.01 billion, u
EARNINGS | Jul 30, 2026, 08:30 AM UTC
L
GCTK - closed +70% in AHs session (uber Nano-cap) PR: Glucotrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Tow
GCTK - closed +70% in AHs session (uber Nano-cap) PR: Glucotrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Ad
REGULATION | Jul 30, 2026, 01:14 AM UTC
M
GCTK Advances LT-100 Development
GCTK advances LT-100 development strategy
EQUITY | Jul 29, 2026, 09:31 PM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
H
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Shares of Callan JMB Inc (NASDAQ: CJMB ) rose sharply in pre-market trading following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical ma
MACRO | Jul 17, 2026, 08:48 AM UTC
H
Top Premarket Gainers
() -- The GrowHub (TGHL) stock was 45% higher, adding to a 3.9% gain in the previous session. GlucoTrack (GCTK) stock was 35% higher after the company completed its merger with Lokahi Therapeutics. Aehr Test Systems (AEH
EARNINGS | Jul 15, 2026, 11:09 AM UTC
H
Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Aehr Test Systems (NASDAQ: AEHR ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY27 sales guidance above estimates. Aehr Test Sy
MACRO | Jul 15, 2026, 08:32 AM UTC
H
GlucoTrack, Lokahi Therapeutics Complete Merger
() -- GlucoTrack (GCTK) has completed its merger with Lokahi Therapeutics, establishing a platform to identify, acquire, and advance healthcare assets. The combined organization integrates Lokahi's late-stage clinical de
MNA | Jul 15, 2026, 08:09 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Thursday's after-market session, with Shuttle Pharmaceuticals and INVO Fertility among the gainers and Creative Medical Tech and Catheter Precision among the losers
EQUITY | Jun 25, 2026, 09:05 PM UTC